Chevy Chase Trust Holdings LLC Lowers Position in DexCom, Inc. (NASDAQ:DXCM)

Chevy Chase Trust Holdings LLC cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 205,088 shares of the medical device company's stock after selling 9,886 shares during the period. Chevy Chase Trust Holdings LLC owned about 0.05% of DexCom worth $15,950,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Versant Capital Management Inc bought a new stake in shares of DexCom in the fourth quarter worth $25,000. Riverview Trust Co grew its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock worth $31,000 after purchasing an additional 232 shares during the last quarter. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the fourth quarter worth $38,000. RPg Family Wealth Advisory LLC bought a new stake in shares of DexCom in the third quarter worth $57,000. Finally, Covestor Ltd grew its stake in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company's stock worth $64,000 after purchasing an additional 335 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at DexCom

In other news, COO Jacob Steven Leach sold 2,634 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Jereme M. Sylvain sold 2,090 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the transaction, the executive vice president now owns 83,526 shares of the company's stock, valued at $7,259,244.66. The trade was a 2.44 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of DexCom stock traded down $0.85 during trading hours on Wednesday, hitting $89.68. 3,037,089 shares of the company's stock traded hands, compared to its average volume of 3,632,174. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The stock has a market capitalization of $35.03 billion, a price-to-earnings ratio of 62.71, a PEG ratio of 2.31 and a beta of 1.14. The company has a fifty day simple moving average of $82.65 and a 200-day simple moving average of $75.62. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts anticipate that DexCom, Inc. will post 1.98 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on DXCM. Morgan Stanley upped their price target on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Citigroup upped their price target on shares of DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Finally, Wells Fargo & Company increased their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 11th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $99.06.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.